Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
Until such time as the company are valued on real present tense income there will always be the likleyhood of a raise at some point. The question you should ask is does the current price undervalue the asset that the company are building. If you get diluted a bit, so what, every early stage investor has to take that as a given. For me, at the moment, this represents outstanding value, and trying to finese an entry price is to risk missing out on a great opportunity, and endlessly talking about it, drive more level headed people nuts.
These are very sick patients. All sorts of reasons you might hold off doses over such a long period. We are obviously looking at very good news here, but it is easy to see 2+2 and conclude 5 without full sight of the data. Beware over interpretation.
At the moment the design is that patients are randomised onto 1 of 3 arms, one of which is straight doxarubicin. They plan to recruit 12 patients to it, and yes bad luck if you draw that card. I suspect / hope that they will be the final ones in the trial. Crucially they will provide biopsy data on the quantity of doxarubicin deposited in the tumor without the help of 6K
That is what upsets me somewhat. I have received zero reward for risking my capital with an early entry. Buying now, into a project with very little downside on the science side that I can see, is just a gift. So far the mince hypothesis is being proven decisively.
Old Frog Throttler is making a bit of a fool of himself this morning. Any guesses as to who had been joining in on the selling jamboree of the past couple of weeks ? So many huckster punks out there, just sickening.
You are aware, I hope, that Avacta recently bought a company in Belgium that major in the diagnosis of bacterial infection. Still, never let an unfortunate fact get in the way of a good story.
I think two reasons. One is to make sure there is enough headroom on the dosing so that they can be confident of getting very low AE's in the 1b. This will significantly strengthen the dataset. Second is they there could be as yet unseen therapeutic benefits from higher doses, particularly as you move into a different patient group, ie STS, your actualy target group for efficacy. There is also the 6K vs the platform issue. A delay in progressing 6K would be repaid many times over by a widening of the scope of the platform. I'm confident they know exactly what they are doing.